In This Issue
Page 1 to 6 of 6 |
Drug Discovery World Winter 2018/19 - Issue Summary
All of the articles in this edition of DDW are, in one way or another, aimed at improving the processes of selecting and progressing through development drug candidates which stand a good chance of achieving eventual regulatory approval within a shorter timeframe and at a lower cost than is currently the case.

Read More

Drug Discovery World Fall 2018 - Issue Summary Dr. Roger Brimblecombe
It has become increasingly apparent in the last decade or so that the traditional processes used in drug discovery and development organisations in the search for new therapeutic agents are no longer fit for purpose.

Read More

Drug Discovery World Summer 2018 - Issue Summary Dr. Roger Brimblecombe
As usual, some of the articles in this number of DDW are devoted to suggestions as to how to improve and accelerate the processes of drug discovery and development and, in particular, to rectify what in one article is described as "the staggering clinical trial failure rate of experimental drugs".

Read More

Drug Discovery World Spring 2018 - Issue Summary Dr. Roger Brimblecombe
Several articles in recent additions of Drug Discovery World have pointed out that the chances of producing meaningful therapeutic advances in a timely and cost-effective manner are increased significantly if there are appropriate collaborations between organisations with complementary skills and experience.

Read More

Drug Discovery World Winter 2017/18 - Issue Summary Dr. Roger Brimblecombe
A recurrent theme in recent numbers of Drug Discovery World has been the increasing necessity for large companies to form relationships with smaller companies, contract research organisations and academia in the search for new leads to potential novel, safe and effective medicines and to expedite their development.

Read More

Drug Discovery World Fall 2017 - Issue Summary Dr Roger Brimblecombe
This issue of DDW, as always, carries a series of articles all of which reflect, in one way or another, the matters which are currently exercising the minds of those involved in drug discovery. For a considerable time now the most common theme by far has been the increasing price of drugs due largely to increased development costs which, in turn, are due in large part to the costs incurred by compounds which fail in the development process, especially in the later stages.

Read More

In This Issue
Page 1 to 6 of 6 |